MedTrace Logo

Phase 2 Trial of Chidamide-Lenalidomide-Dexamethasone(CRD) Regimen in R/R MM

NCT03605056 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2018-07-30

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and effectiveness of combination of Chidamide-Lenalidomine-Dexamethasone in relapsed or refractory multiple myeloma patients

Conditions

Interventions

DRUG

chidamide

20 mg/d, will be administered orally, on Days 1, 4, 8, 11 of each 21 day cycle

DRUG

lenalidomide

25 mg/d, will be administered orally on Days 1-14 each 21 day cycle

DRUG

dexamethasone

40mg weekly, will be administered orally or intravenously

Sponsors & Collaborators

  • Chipscreen Biosciences, Ltd.

    collaborator INDUSTRY

  • Peng Liu

    lead OTHER

Principal Investigators

  • Peng Liu, MD,PhD · Shanghai Zhongshan Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-31
Primary Completion
2020-07-31
Completion
2022-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03605056 on ClinicalTrials.gov